Treating tumors using implants comprising combinations of allogeneic cells
AssigneeThe Regents of the University of California
InventorsGale Arthur Granger, John C. Hiserodt, James Thompson
Life of this patent
Estimating the term…
Abstract
This invention provides methods and compositions for treating tumors. The cell population is made up of alloactivated lymphocytes from the patient or from one or more third-party donors that are alloactivated in a mixed lymphocyte culture. It can be placed into the tumor bed, or combined with tumor-associated antigen for administration to a distal site as a vaccine. The compositions recruit activated participation of the host Immune system, which then reacts against the tumor and provides a level of ongoing protection. Employing multiple third party donor cells confers particular advantages in terms of effectiveness, timing, and ease of use.
Claims39
A method for eliciting an anti-tumor immunological response in a human patient who has cancer, comprising administering to the patient a pharmaceutical composition comprising alloactivated lymphocytes from two or more different human donors who are each unrelated to the patient, in a compatible pharmaceutical excipient.
A method for treating cancer in a human patient, comprising administering to the patient a pharmaceutical composition comprising alloactivated lymphocytes from two or more different human donors who are each unrelated to the patient, in a compatible pharmaceutical excipient.
A method for treating cancer in a human patient, comprising administering to the patient a pharmaceutical composition made with naturally occurring human lymphocytes allogeneic to the patient and with a tumor associated antigen combined in a compatible pharmaceutical excipient.
A method for eliciting an anti-tumor immunological response in a human patient who has cancer, comprising administering to the patient a pharmaceutical composition made with naturally occurring human lymphocytes allogeneic to the patient and with a tumor associated antigen combined in a compatible pharmaceutical excipient.
The method of clam 21, wherein step b) further comprises culturing the lymphocytes from the two donors together so that the lymphocytes become alloactivated.
The method of clam 23, wherein the tumor cells have been obtained from the patient being treated.
A method for eliciting an anti-tumor immunological response in a human patient who has cancer, comprising administering to the patient an immunogenic composition that has been made by the following process:
- a) obtaining leukocytes from donor(s) allogeneic to the patient by leukapheresis or whole blood donation;
- b) processing said leukocytes to obtain a population of naturally occurring peripheral blood mononuclear cells (PBMCs);
- c) washing and suspending the population of naturally occurring PBMCs in a suitable medium to produce suspended cells;
- d) combining the suspended cells with at least one tumor associated antigen (TAA) that is also expressed on a tumor in the patient to produce a combination;
- and
- e) formulating said combination as a pharmaceutical composition for administration to a human patient by injection.
The method of clam 26, wherein the PBMCs were alloactivated.
A method for eliciting an anti-tumor immunological response in a human patient who has cancer, comprising administering to the patient an immunogenic composition that has been made by the following process:
- a) obtaining leukocytes by leukapheresis or whole blood donation;
- b) processing said leukocytes to obtain a population of naturally occurring peripheral blood mononuclear cells (PBMCs);
- c) washing and suspending the population of naturally occurring PBMCs in a suitable medium to produce suspended cells;
- d) combining the suspended cells with tumor cells allogeneic to the patient, or an extract obtainable from such cells to produce a combination;
- and
- e) formulating said combination as a pharmaceutical composition for administration to a human patient by injection.
Dependencies are inferred from the claim text.